Skip to main content

Table 2 Changes in collagen biomarker levels and ASDAS improvement categories from baseline to weeks 22 and 46, respectively

From: Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapy

Biomarker

Baseline to week 22

Baseline to week 46

No improvement

(n=17)

Clinically important improvement

(n=10)

Major improvement

(n=23)

P-value

No improvement

(n=11)

Clinically important improvement

(n=13)

Major improvement

(n=17)

P value

PRO-C1

Median (IQR)

0.1

(− 32.8, 7.8)

7.6

(− 3.5, 16.0)

29.5

(9.2, 44.7)

0.006

0.1

(− 32.6, 8.8)

28.4

(5.9, 47.3)

33.8

(6.5, 52.3)

0.006

PRO-C3

Median (IQR)

− 13.1

(− 32.4, − 3.2)

3.2

(− 3.9, 9.0)

12.6

(− 1.4, 32.9)

0.008

6.3

(− 3.9, 25.5)

− 3.9

(− 16.0, 13.2)

5.7

(− 2.2, 29.0)

0.573

PRO-C4

Median (IQR)

10.2

(− 12.7, 20.3)

− 14.0

(− 24.3, 10. 6)

− 15.6

(− 37.5, 0.9)

0.114

3.6

(− 22.5, 15.7)

17.7

(− 15.6, 22.4)

− 24.2

(− 43.0, − 8.4)

0.048

PRO-C6

Median (IQR)

− 6.7

(− 13.9, 0.0)

0.3

(− 13.2, 10.7)

7.6

(− 6.4, 23.6)

0.063

0.3

(− 2.5, 17.5)

7.6

(− 12.3, 17.3)

6.2

(− 6.9, 21.4)

0.915

C3M

Median (IQR)

7.9

(− 3.1, 18.9)

20.4

(11.3, 22.2)

2.9

(− 14.4, 11.8)

0.152

11.1

(0.7, 19.7)

8.3

(− 3.1, 20.9)

2.9

(− 14.3, 9.8)

0.318

C4M

Median (IQR)

− 7.2

(− 14.8, 8.8)

5.0

(− 22.3, 16.4)

− 6.8

(− 11.4, 6.9)

0.899

− 2.0

(− 9.1, 5.9)

− 11.5

(− 30.8, − 7.7)

− 0.3

(− 9.7, 11.1)

0.153

C6M

Median (IQR)

12.4

(− 34.8, 22.3)

− 20.2

(− 29.8, 19.9)

− 54.3

(− 70.8, − 30.1)

< 0.001

12.0

(− 25.4, 37.1)

− 1.9

(− 43.2, 22.3)

− 62.1

(− 73.7, − 30.0)

0.007

C7M

Median (IQR)

− 26.9

(− 31.1, 35.3)

− 33.5

(− 64.5, − 17.1)

− 32.2

(− 55.4, 0.0)

0.192

− 29.1

(− 43.6, 41.0)

− 26.9

(− 39.0, 0.0)

− 46.6

(− 56.9, − 4.5)

0.447

C10C

Median (IQR)

2.8

(− 9.3, 17.6)

17.4

(5.3, 23.9)

2.1

(− 6.1, 15.5)

0.216

19.7

(10.1, 22.7)

0.5

(− 9.9, 12.4)

4.0

(− 4.7, 14.5)

0.165

CRPM

Median (IQR)

− 2.3

(− 8.6, 5.1)

− 1.3

(− 4.8, 20.5)

2.5

(− 16.3, 15.1)

0.541

5.1

(− 0.8, 23.0)

− 5.1

(− 9.1, 1.4)

− 1.1

(− 25.4, 10.4)

0.248

EL-NE

Median (IQR)

0.0

(− 17.2, 9.1)

1.2

(0.0, 24.9)

0.0

(− 33.1, 0.0)

0.108

0.0

(− 8.6, 1.4)

0.0

(− 30.0, 29.3)

0.0

(− 31.7, 0.0)

0.414

VICM

Median (IQR)

29.1

(− 17.3, 107.4)

− 72.1

(− 80.1, − 58.0)

− 43.3

(− 65.3, − 0.7)

< 0.001

0.0

(− 35.8, 47.8)

− 34.7

(− 64.9, − 18.8)

− 63.8

(− 69.7, − 37.9)

0.044

CRP

Median (IQR)

− 1.7

(− 4.93 to − 0.63)

− 9.2

(− 24.80–5.30)

− 24.9

(− 61.40 to − 12.70)

<0.001

12.3

(8.00–27.68)

− 1.50

(9.500–5.58)

− 7.00

(65.25–1.25)

<0.001

  1. PRO-C1 type I collagen formation, PRO-C3 type III collagen formation, PRO-C4 type IV collagen turnover, PRO-C6 type VI collagen formation, C3M degradation of type III collagen, C4M degradation of type IV collagen, C6M degradation of type VI collagen, C7M degradation of type VII collagen, C10C degradation of type X collagen, CRPM degradation of C-reactive protein, EL-NE degradation of elastin, VICM degraded and citrullinated vimentin, CRP C-reactive protein, IQR inter quartile range
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us